Viking Therapeutics (VKTX) Stock Forecast & Price Target

Compare

6,932 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

VKTX Analyst Ratings

Strong Buy

15 Buy

2 Hold

0 Sell

Based on 17 analysts giving stock ratings to

Viking

Therapeutics

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

VKTX Stock 12 Month Forecast

Average Price Target

$90.20

▲(187.08% Upside)

Based on 17 Wall Street analysts offering 12 month price targets for Viking Therapeutics in the last 3 months. The average price target is $90.20 with a high forecast of $125.00 and a low forecast of $29.00. The average price target represents a 187.08% change from the last price of $31.42.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"22":"$22","48":"$48","74":"$74","100":"$100","126":"$126"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":125,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$125.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":90.2,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$90.20</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":29,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$29.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[22,48,74,100,126],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2025","6":"Apr<br/>2025","9":"Jul<br/>2025","12":"Oct<br/>2025","25":"Oct<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,27.37,34.88,42.39,49.900000000000006,57.41,64.92,72.43,79.94,87.45,94.96000000000001,102.47,109.98,117.49000000000001,{"y":125,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,27.37,32.20307692307692,37.036153846153844,41.86923076923077,46.70230769230769,51.535384615384615,56.36846153846153,61.20153846153846,66.03461538461538,70.86769230769231,75.70076923076923,80.53384615384616,85.36692307692307,{"y":90.2,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,27.37,27.495384615384616,27.62076923076923,27.746153846153845,27.871538461538464,27.99692307692308,28.122307692307693,28.247692307692308,28.373076923076923,28.498461538461537,28.623846153846156,28.74923076923077,28.874615384615385,{"y":29,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":62,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":72.88,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":51.51,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":40.24,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32.75,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.87,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.91,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 46,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.62,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.12,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.67,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32.68,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.49,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.37,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$125.00

Average Price Target$90.20

Lowest Price Target$29.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Annabel Samimy

Stifel Nicolaus

$95

Buy

202.36%

Upside

Reiterated

10/23/25

Steven Seedhouse

Cantor Fitzgerald

$104→$105

Buy

234.18%

Upside

Reiterated

10/23/25

Viking Therapeutics offered 'transformative' Q3 update, says Cantor FitzgeraldViking Therapeutics offered 'transformative' Q3 update, says Cantor Fitzgerald

Andy Hsieh

William Blair

―

Buy

―

Reiterated

10/23/25

Viking Therapeutics Gains Buy Rating Amid Promising Obesity Treatment Developments and Strategic Advancements

Michael Ulz

Morgan Stanley

$98→$102

Buy

224.63%

Upside

Reiterated

10/23/25

Promising Clinical Progress and Accelerated Enrollment Drive Buy Rating for Viking TherapeuticsWe are encouraged by swift execution across programs; Reiterate Overweight.

Biren Amin

Piper Sandler

$71

Buy

125.97%

Upside

Reiterated

10/23/25

Analysts Offer Insights on Healthcare Companies: Geron (NASDAQ: GERN), Viking Therapeutics (NASDAQ: VKTX) and Neurocrine (NASDAQ: NBIX)VKTX (US$31.42) Overweight US$71.00 PT

Justin Zelin

BTIG

$125

Buy

297.84%

Upside

Reiterated

10/23/25

We reiterate our Buy rating and $125 PT.

Joseph Pantginis

H.C. Wainwright

$102

Buy

224.63%

Upside

Reiterated

10/23/25

H.C. Wainwright Keeps Their Buy Rating on Viking Therapeutics (VKTX)We reiterate our Buy rating and $102 price target.

Naz Rahman

Maxim Group

$70

Buy

122.79%

Upside

Reiterated

10/21/25

Analysts Offer Insights on Healthcare Companies: Bausch + Lomb Corporation (NYSE: BLCO) and Viking Therapeutics (NASDAQ: VKTX)

Jay Olson

Oppenheimer

$100

Buy

218.27%

Upside

Reiterated

10/07/25

Analysts Offer Insights on Healthcare Companies: ClearPoint Neuro (NASDAQ: CLPT), BioLife Solutions (NASDAQ: BLFS) and Viking Therapeutics (NASDAQ: VKTX)

David Lebowitz

Citi

$38→$29

Hold

-7.70%

Downside

Reiterated

08/20/25

Viking Therapeutics (VKTX) Gets a Hold from Citi

Yale Jen

Laidlaw

$110

Buy

250.10%

Upside

Reiterated

08/20/25

Laidlaw Keeps Their Buy Rating on Viking Therapeutics (VKTX)Laidlaw analyst Yale Jen reiterated a Buy rating and $110.00 price target on Viking Therapeutic (NASDAQ: VKTX).

Joon Lee

Truist Financial

$75

Buy

138.70%

Upside

Reiterated

08/19/25

Truist Financial Sticks to Its Buy Rating for Viking Therapeutics (VKTX)

Thomas Smith

Leerink Partners

$118

Buy

275.56%

Upside

Reiterated

08/19/25

Viking Therapeutics weakness 'overdone,' says LeerinkViking Therapeutics weakness 'overdone,' says Leerink

Ryan Deschner

Raymond James

$122

Buy

288.29%

Upside

Reiterated

08/19/25

Raymond James Reaffirms Their Buy Rating on Viking Therapeutics (VKTX)

Hardik Parikh

J.P. Morgan

―

Buy

―

Reiterated

08/19/25

JPMorgan says Viking weight loss drug still offers strong efficacy JPMorgan says Viking weight loss drug still offers strong efficacy

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Annabel Samimy

Stifel Nicolaus

$95

Buy

202.36%

Upside

Reiterated

10/23/25

Steven Seedhouse

Cantor Fitzgerald

$104→$105

Buy

234.18%

Upside

Reiterated

10/23/25

Viking Therapeutics offered 'transformative' Q3 update, says Cantor FitzgeraldViking Therapeutics offered 'transformative' Q3 update, says Cantor Fitzgerald

Andy Hsieh

William Blair

―

Buy

―

Reiterated

10/23/25

Viking Therapeutics Gains Buy Rating Amid Promising Obesity Treatment Developments and Strategic Advancements

Michael Ulz

Morgan Stanley

$98→$102

Buy

224.63%

Upside

Reiterated

10/23/25

Promising Clinical Progress and Accelerated Enrollment Drive Buy Rating for Viking TherapeuticsWe are encouraged by swift execution across programs; Reiterate Overweight.

Biren Amin

Piper Sandler

$71

Buy

125.97%

Upside

Reiterated

10/23/25

Analysts Offer Insights on Healthcare Companies: Geron (NASDAQ: GERN), Viking Therapeutics (NASDAQ: VKTX) and Neurocrine (NASDAQ: NBIX)VKTX (US$31.42) Overweight US$71.00 PT

Justin Zelin

BTIG

$125

Buy

297.84%

Upside

Reiterated

10/23/25

We reiterate our Buy rating and $125 PT.

Joseph Pantginis

H.C. Wainwright

$102

Buy

224.63%

Upside

Reiterated

10/23/25

H.C. Wainwright Keeps Their Buy Rating on Viking Therapeutics (VKTX)We reiterate our Buy rating and $102 price target.

Naz Rahman

Maxim Group

$70

Buy

122.79%

Upside

Reiterated

10/21/25

Analysts Offer Insights on Healthcare Companies: Bausch + Lomb Corporation (NYSE: BLCO) and Viking Therapeutics (NASDAQ: VKTX)

Jay Olson

Oppenheimer

$100

Buy

218.27%

Upside

Reiterated

10/07/25

Analysts Offer Insights on Healthcare Companies: ClearPoint Neuro (NASDAQ: CLPT), BioLife Solutions (NASDAQ: BLFS) and Viking Therapeutics (NASDAQ: VKTX)

David Lebowitz

Citi

$38→$29

Hold

-7.70%

Downside

Reiterated

08/20/25

Viking Therapeutics (VKTX) Gets a Hold from Citi

Yale Jen

Laidlaw

$110

Buy

250.10%

Upside

Reiterated

08/20/25

Laidlaw Keeps Their Buy Rating on Viking Therapeutics (VKTX)Laidlaw analyst Yale Jen reiterated a Buy rating and $110.00 price target on Viking Therapeutic (NASDAQ: VKTX).

Joon Lee

Truist Financial

$75

Buy

138.70%

Upside

Reiterated

08/19/25

Truist Financial Sticks to Its Buy Rating for Viking Therapeutics (VKTX)

Thomas Smith

Leerink Partners

$118

Buy

275.56%

Upside

Reiterated

08/19/25

Viking Therapeutics weakness 'overdone,' says LeerinkViking Therapeutics weakness 'overdone,' says Leerink

Ryan Deschner

Raymond James

$122

Buy

288.29%

Upside

Reiterated

08/19/25

Raymond James Reaffirms Their Buy Rating on Viking Therapeutics (VKTX)

Hardik Parikh

J.P. Morgan

―

Buy

―

Reiterated

08/19/25

JPMorgan says Viking weight loss drug still offers strong efficacy JPMorgan says Viking weight loss drug still offers strong efficacy

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Viking Therapeutics

1 Month

xxx

Success Rate

13/21 ratings generated profit

Average Return

+12.93%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 61.90% of your transactions generating a profit, with an average return of +12.93% per trade.

3 Months

xxx

Success Rate

13/22 ratings generated profit

Average Return

+21.46%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 59.09% of your transactions generating a profit, with an average return of +21.46% per trade.

1 Year

Naz RahmanMaxim Group

Success Rate

16/22 ratings generated profit

Average Return

+148.37%

reiterated a buy rating 2 months ago

Copying Naz Rahman's trades and holding each position for 1 Year would result in 72.73% of your transactions generating a profit, with an average return of +148.37% per trade.

2 Years

xxx

Success Rate

17/22 ratings generated profit

Average Return

+223.05%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 77.27% of your transactions generating a profit, with an average return of +223.05% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

VKTX Analyst Recommendation Trends

Rating

Jun 25

Jul 25

Aug 25

Sep 25

Oct 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, VKTX has received 23 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. VKTX average Analyst price target in the past 3 months is 90.20.

Each month's total comprises the sum of three months' worth of ratings.

VKTX Financial Forecast

VKTX Earnings Forecast

Next quarter’s earnings estimate for VKTX is -$0.86 with a range of -$1.06 to -$0.76. The previous quarter’s EPS was -$0.81. VKTX beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.09% of the time in the same period. In the last calendar year VKTX has Preformed in-line its overall industry.

No data currently available

VKTX Sales Forecast

Next quarter’s sales forecast for VKTX is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. VKTX beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 47.55% of the time in the same period. In the last calendar year VKTX has Preformed in-line its overall industry.

VKTX Stock Forecast FAQ

What is VKTX’s average 12-month price target, according to analysts?

Based on analyst ratings, Viking Therapeutics’s 12-month average price target is 90.20.

What is VKTX’s upside potential, based on the analysts’ average price target?

Viking Therapeutics has 187.08% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is VKTX a Buy, Sell or Hold?

Viking Therapeutics has a consensus rating of Strong Buy which is based on 15 buy ratings, 2 hold ratings and 0 sell ratings.

What is Viking Therapeutics’s price target?

The average price target for Viking Therapeutics is 90.20. This is based on 17 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $125.00 ,the lowest forecast is $29.00. The average price target represents 187.08% Increase from the current price of $31.42.

What do analysts say about Viking Therapeutics?

Viking Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 17 Wall Streets Analysts.

How can I buy shares of VKTX?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Viking Therapeutics (VKTX) Stock Forecast & Price Target

VKTX Analyst Ratings

VKTX Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Viking Therapeutics

VKTX Analyst Recommendation Trends

VKTX Financial Forecast

VKTX Earnings Forecast

VKTX Sales Forecast

VKTX Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts